

Provided by:



Neuroendocrine Tumor Board 2025-2026 2026

Neuroendocrine Tumor Board 2025-2026 - 3/6/2026

March 6, 2026

7:00 AM - 8:00 AM

Virtual Platform - Microsoft Teams

Target Audience

This program has been designed for FAMILY MEDICINE, PEDIATRICS, INTERVENTIONAL RADIOLOGY AND DIAGNOSTIC RADIOLOGY, NUCLEAR MEDICINE, RADIATION ONCOLOGY, SURGERY, INTERNAL MEDICINE, OTOLARYNGOLOGY, PATHOLOGY-ANATOMIC/PATHOLOGY-CLINICAL, GENETICS

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss appropriate, comprehensive, multidisciplinary best practice treatment plans for NET patients and their families
- 2 Describe an in-depth knowledge of the various imaging techniques and treatment options for the diagnosis, surveillance and treatment of NET patient.
- 3 Discuss the rapidly evolving field of neuroendocrinology through analysis of best medical practices and research
- 4 Discuss how to strengthen professionalism among the multidisciplinary team participants

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit:

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours.

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*: None

For more information, please contact
Bonita Bennett, Maria Bonanni
(215) 349-5562, (609) 338-7824

bonita.bennett@uphs.upenn.edu, Maria.Bonanni@pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Bonita J. Bennett, BSN	Faculty, Nurse Planner	Nothing to disclose - 07/24/2025
Maria L Bonanni, CRNP	Nurse Planner	Paid consultant-Medtronic - 08/26/2025
Keith Cengel, MD, PhD	Other Planning Committee Member	Nothing to disclose - 07/17/2025
William Chapin, MD	Other Planning Committee Member	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Replimune Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merus Grant or research support-Merus Grant or research support-Genentech Grant or research support-Replimune Grant or research support-Boehringer-Ingelheim Other: Travel Support - Dava Oncology (Relationship has ended) - 05/22/2025
Debbie Cohen Stein, MD	Co-Director	Consulting Fee-Medtronic Consulting Fee-Novartis / Amgen Advisor-Metavention (Relationship has ended) Consulting Fee-Recor Consulting Fee-Kardigan - 06/12/2025
Nevena Damjanov, MD	Other Planning Committee Member	Nothing to disclose - 07/13/2025
Daniel Depietro, MD	Co-Director, Faculty, Other Planning Committee Member	Nothing to disclose - 09/25/2025
Efrat Dotan, MD	Other Planning Committee Member	Advisor-Ipsen (Relationship has ended) Grant or research support-Relay (Relationship has ended) Consulting Fee-Lutris Pharmaceuticals (Relationship has

		ended) Grant or research support-Lutris (Relationship has ended) Consulting Fee-Jazz Pharmaceuticals Advisor-AbbVie, Inc. (Relationship has ended) Advisor-TME Therapeutics (Relationship has ended) Advisor-Merus (Relationship has ended) Advisor-Amgen (Relationship has ended) Advisor-Agenus (Relationship has ended) Advisor-Merck & Co (Relationship has ended) Grant or research support-Ipsen - 11/28/2025
Jennifer Eads, MD	Co-Director	Advisor-Lilly (Relationship has ended) Advisor-Boehringer-Ingelheim Advisor-Oncolys (Relationship has ended) Advisor-Exelixis (Relationship has ended) Advisor-Daiichi Sankyo (Relationship has ended) Advisor-Lantheus (Relationship has ended) Grant or research support-Arcus (Relationship has ended) Grant or research support-Crinetics Grant or research support-Amgen Grant or research support-Chimeric Therapeutics Grant or research support-Gilead Sciences, Inc (Relationship has ended) Grant or research support-Hutchmed (Relationship has ended) Grant or research support-Merck & Co Grant or research support-Seagen (Relationship has ended) Grant or research support-Boehringer-Ingelheim (Relationship has ended) - 09/25/2025
Rachel Fife, PA-C	Physician Assistant Planner	Nothing to disclose - 10/01/2025
Douglas Fraker, MD	Other Planning Committee Member	Nothing to disclose - 10/12/2025
Yonghong Huan, MD	Other Planning Committee Member	Nothing to disclose - 09/09/2025
Ryan Massa, MD	Other Planning Committee Member	Nothing to disclose - 11/24/2025
Philipose Mulugeta, MD	Other Planning Committee Member	Consulting Fee-Telix Consulting Fee-Lantheus Grant or research support-Telix Grant or research support-Bristol-Myers Squibb Grant or research support-Curium (Relationship has ended) Grant or research support-American Cancer Society Grant or research support-Elily Lilly and Company Consulting Fee-Novartis / Amgen (Relationship has ended) - 09/02/2025
Katherine L Nathanson, MD	Other Planning Committee Member	Nothing to disclose - 07/20/2025
Sophia O'Brien, MD	Other Planning Committee Member	Consulting Fee-GE Healthcare (Relationship has ended) - 10/18/2025
Christopher Rassekh, MD	Other Planning Committee Member	Consulting Fee-RiboX - 10/01/2025
Robert E Roses, MD	Other Planning Committee Member	Nothing to disclose - 04/10/2025

Charles J Schneider, MD	Other Planning Committee Member	Nothing to disclose - 09/08/2025
Aditi Singh, MD	Other Planning Committee Member	Grant or research support-Jazz Pharmaceuticals - Institutional funding (Relationship has ended) Grant or research support-Gilead Sciences, Inc - 11/13/2025
Michael Soulen, MD	Other Planning Committee Member	Grant or research support-Guerbet LLC Grant or research support-Pfizer, Inc. (Relationship has ended) Grant or research support-Sirtex Consulting Fee-Guerbet LLC Consulting Fee-Instylla Advisor-Genentech (Relationship has ended) Advisor-Astra Zeneca Pharmaceuticals - 10/12/2025
Ursina Teitelbaum, MD	Other Planning Committee Member	Nothing to disclose - 01/30/2026
Heather Wachtel, MD	Other Planning Committee Member	Nothing to disclose - 02/10/2026
Heather T Warren, CRNP RN	Other Planning Committee Member	Nothing to disclose - 10/13/2025
Zhaohai Yang, MD	Other Planning Committee Member	Consulting Fee-Flagship Biosciences - 07/10/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected